Inozyme Pharma, Inc.

NasdaqGS:INZY Stock Report

Market Cap: US$180.5m

Inozyme Pharma Balance Sheet Health

Financial Health criteria checks 5/6

Inozyme Pharma has a total shareholder equity of $82.8M and total debt of $45.6M, which brings its debt-to-equity ratio to 55.1%. Its total assets and total liabilities are $143.4M and $60.6M respectively.

Key information

55.1%

Debt to equity ratio

US$45.64m

Debt

Interest coverage ration/a
CashUS$131.61m
EquityUS$82.79m
Total liabilitiesUS$60.57m
Total assetsUS$143.36m

Recent financial health updates

Recent updates

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Nov 17
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Aug 03
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Jul 30

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Apr 11
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Mar 08

Inozyme Pharma GAAP EPS of -$0.38

Aug 15

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Jul 19

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Jul 12
Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Apr 06
We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Dec 22
Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Sep 08
Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

May 22
We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

May 07

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Feb 06
We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Jan 04

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Dec 03

Inozyme Pharma EPS misses by $1.02

Nov 12

Financial Position Analysis

Short Term Liabilities: INZY's short term assets ($140.9M) exceed its short term liabilities ($18.3M).

Long Term Liabilities: INZY's short term assets ($140.9M) exceed its long term liabilities ($42.2M).


Debt to Equity History and Analysis

Debt Level: INZY has more cash than its total debt.

Reducing Debt: INZY's debt to equity ratio has increased from 0% to 55.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INZY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: INZY has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 26.7% each year.


Discover healthy companies